These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 15870879

  • 1. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.
    Collado B, Carmena MJ, Sánchez-Chapado M, Ruíz-Villaespesa A, Bajo AM, Fernández-Martínez AB, Varga JL, Schally AV, Prieto JC.
    Int J Oncol; 2005 Jun; 26(6):1629-35. PubMed ID: 15870879
    [Abstract] [Full Text] [Related]

  • 2. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.
    García-Fernández MO, Collado B, Bodega G, Cortés J, Ruíz-Villaespesa A, Carmena MJ, Prieto JC.
    Gynecol Endocrinol; 2005 Jun; 20(6):327-33. PubMed ID: 16019382
    [Abstract] [Full Text] [Related]

  • 3. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M, Muciaccia B, Morelli MB, Stefanini M, Cecconi S, Canipari R.
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [Abstract] [Full Text] [Related]

  • 4. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
    Nagakawa O, Junicho A, Akashi T, Koizumi K, Matsuda T, Fuse H, Saiki I.
    Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
    [Abstract] [Full Text] [Related]

  • 5. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D, Anouar Y, Jegou S, Fournier A, Vaudry H.
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [Abstract] [Full Text] [Related]

  • 6. Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.
    Rekasi Z, Varga JL, Schally AV, Halmos G, Groot K, Czompoly T.
    Proc Natl Acad Sci U S A; 2000 Feb 01; 97(3):1218-23. PubMed ID: 10655511
    [Abstract] [Full Text] [Related]

  • 7. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L, Ahrén B, Edgren G, Degerman E.
    Endocrinology; 2005 Feb 01; 146(2):744-50. PubMed ID: 15514088
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
    Plonowski A, Varga JL, Schally AV, Krupa M, Groot K, Halmos G.
    Int J Cancer; 2002 Apr 01; 98(4):624-9. PubMed ID: 11920625
    [Abstract] [Full Text] [Related]

  • 9. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.
    Solano RM, Carmena MJ, Busto R, Sánchez-Chapado M, Guijarro LG, Prieto JC.
    Cell Signal; 1999 Nov 01; 11(11):813-9. PubMed ID: 10617284
    [Abstract] [Full Text] [Related]

  • 10. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
    Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA.
    Cancer Res; 2000 Jun 01; 60(11):3105-12. PubMed ID: 10850463
    [Abstract] [Full Text] [Related]

  • 11. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
    Sotomayor S, Carmena MJ, Schally AV, Varga JL, Sánchez-Chapado M, Prieto JC, Bajo AM.
    Int J Oncol; 2007 Nov 01; 31(5):1223-30. PubMed ID: 17912451
    [Abstract] [Full Text] [Related]

  • 12. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM, Carmena MJ, Carrero I, Cavallaro S, Roman F, Hueso C, Travali S, Lopez-Fraile N, Guijarro LG, Prieto JC.
    Endocrinology; 1996 Jul 01; 137(7):2815-22. PubMed ID: 8770902
    [Abstract] [Full Text] [Related]

  • 13. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors.
    Juarranz MG, Bolaños O, Gutiérrez-Cañas I, Lerner EA, Robberecht P, Carmena MJ, Prieto JC, Rodríguez-Henche N.
    Cell Signal; 2001 Dec 01; 13(12):887-94. PubMed ID: 11728828
    [Abstract] [Full Text] [Related]

  • 14. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
    Laburthe M, Couvineau A, Rouyer-Fessard C.
    Mol Pharmacol; 1986 Jan 01; 29(1):23-7. PubMed ID: 3003561
    [Abstract] [Full Text] [Related]

  • 15. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
    Vaccari S, Latini S, Barberi M, Teti A, Stefanini M, Canipari R.
    J Endocrinol; 2006 Oct 01; 191(1):287-99. PubMed ID: 17065411
    [Abstract] [Full Text] [Related]

  • 16. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
    Goursaud S, Pineau N, Becq-Giraudon L, Gressens P, Muller JM, Janet T.
    J Neuroimmunol; 2005 Jan 01; 158(1-2):94-105. PubMed ID: 15589042
    [Abstract] [Full Text] [Related]

  • 17. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP-receptor type 1 expression in rat and human placenta.
    Scaldaferri ML, Modesti A, Palumbo C, Ulisse S, Fabbri A, Piccione E, Frajese G, Moretti C.
    Endocrinology; 2000 Mar 01; 141(3):1158-67. PubMed ID: 10698193
    [Abstract] [Full Text] [Related]

  • 18. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
    Rekasi Z, Varga JL, Schally AV, Halmos G, Armatis P, Groot K, Czompoly T.
    Endocrinology; 2000 Jun 01; 141(6):2120-8. PubMed ID: 10830299
    [Abstract] [Full Text] [Related]

  • 19. Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue.
    García-Fernández MO, Solano RM, Carmena MJ, Busto R, Bodega G, Ruíz-Villaespesa A, Prieto JC, Sánchez-Chapado M.
    Peptides; 2003 Jun 01; 24(6):893-902. PubMed ID: 12948842
    [Abstract] [Full Text] [Related]

  • 20. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
    Mazzocchi G, Malendowicz LK, Neri G, Andreis PG, Ziolkowska A, Gottardo L, Nowak KW, Nussdorfer GG.
    Int J Mol Med; 2002 Mar 01; 9(3):233-43. PubMed ID: 11836629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.